Recent developments in Scribe Therapeutics' IPO process, including its July 2026 S-1 filing and pricing terms of $13–$15 per share targeting roughly $100 million in proceeds, have created balanced trader sentiment across market-cap buckets and the no-IPO outcome. Eli Lilly backing, a clinical pipeline focused on lipid-lowering gene therapies, and approximately $50 million in cash as of March 2026 support a post-offering valuation near $230 million, yet broader biotech IPO volatility, potential underwriter adjustments, and resolution timing before September 2026 introduce meaningful uncertainty. Market-implied odds reflect competing views on first-day closing levels relative to comparable cardiovascular and gene-editing debuts, with upcoming pricing this week serving as the immediate catalyst that could clarify the path.
Eksperymentalne podsumowanie AI odwołujące się do danych Polymarket. To nie jest porada handlowa i nie ma wpływu na rozstrzyganie tego rynku. · Zaktualizowano$85M-$100M 44%
$145M+ 44%
$130M-$145M 42%
$100M-$115M 42%
NOWE
NOWE
Jul 24, 2026
<$85M
40%
$85M-$100M
44%
$100M-$115M
42%
$115M-$130M
42%
$130M-$145M
42%
$145M+
44%
No IPO before September 2026
41%
$85M-$100M 44%
$145M+ 44%
$130M-$145M 42%
$100M-$115M 42%
NOWE
NOWE
Jul 24, 2026
<$85M
$0 Wol.
40%
$85M-$100M
$0 Wol.
44%
$100M-$115M
$0 Wol.
42%
$115M-$130M
$0 Wol.
42%
$130M-$145M
$0 Wol.
42%
$145M+
$0 Wol.
44%
No IPO before September 2026
$0 Wol.
41%
This market will resolve based on Scribe Therapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on July 24 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Recent developments in Scribe Therapeutics' IPO process, including its July 2026 S-1 filing and pricing terms of $13–$15 per share targeting roughly $100 million in proceeds, have created balanced trader sentiment across market-cap buckets and the no-IPO outcome. Eli Lilly backing, a clinical pipeline focused on lipid-lowering gene therapies, and approximately $50 million in cash as of March 2026 support a post-offering valuation near $230 million, yet broader biotech IPO volatility, potential underwriter adjustments, and resolution timing before September 2026 introduce meaningful uncertainty. Market-implied odds reflect competing views on first-day closing levels relative to comparable cardiovascular and gene-editing debuts, with upcoming pricing this week serving as the immediate catalyst that could clarify the path.
This market will resolve based on Scribe Therapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on July 24 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on July 24 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Rynek otwarty: Jul 21, 2026, 6:41 PM ET
Wolumen
$0Data zakończenia
Jul 24, 2026Rynek otwarty
Jul 21, 2026, 6:41 PM ETResolver
0x69c47De9D...This market will resolve based on Scribe Therapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on July 24 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Recent developments in Scribe Therapeutics' IPO process, including its July 2026 S-1 filing and pricing terms of $13–$15 per share targeting roughly $100 million in proceeds, have created balanced trader sentiment across market-cap buckets and the no-IPO outcome. Eli Lilly backing, a clinical pipeline focused on lipid-lowering gene therapies, and approximately $50 million in cash as of March 2026 support a post-offering valuation near $230 million, yet broader biotech IPO volatility, potential underwriter adjustments, and resolution timing before September 2026 introduce meaningful uncertainty. Market-implied odds reflect competing views on first-day closing levels relative to comparable cardiovascular and gene-editing debuts, with upcoming pricing this week serving as the immediate catalyst that could clarify the path.
This market will resolve based on Scribe Therapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on July 24 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on July 24 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Wolumen
$0Data zakończenia
Jul 24, 2026Rynek otwarty
Jul 21, 2026, 6:41 PM ETResolver
0x69c47De9D...Recent developments in Scribe Therapeutics' IPO process, including its July 2026 S-1 filing and pricing terms of $13–$15 per share targeting roughly $100 million in proceeds, have created balanced trader sentiment across market-cap buckets and the no-IPO outcome. Eli Lilly backing, a clinical pipeline focused on lipid-lowering gene therapies, and approximately $50 million in cash as of March 2026 support a post-offering valuation near $230 million, yet broader biotech IPO volatility, potential underwriter adjustments, and resolution timing before September 2026 introduce meaningful uncertainty. Market-implied odds reflect competing views on first-day closing levels relative to comparable cardiovascular and gene-editing debuts, with upcoming pricing this week serving as the immediate catalyst that could clarify the path.
Eksperymentalne podsumowanie AI odwołujące się do danych Polymarket. To nie jest porada handlowa i nie ma wpływu na rozstrzyganie tego rynku. · Zaktualizowano
Uważaj na linki zewnętrzne.
Uważaj na linki zewnętrzne.
Często zadawane pytania